The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The evolving treatment landscape in Hodgkin lymphoma: optimizing outcomes in R/R disease
In this video, John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, comments on the evolving treatment landscape in Hodgkin lymphoma (HL), highlighting the success of novel therapies such as nivolumab in advanced-stage disease and the potential for improved outcomes in the relapsed/refractory (R/R) population. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
